Retinitis Pigmentosa (RP) Completed Phase 1 / 2 Trials for Cenegermin (DB13926)

Also known as: Retinitis Pigmentosa / Pigmentary maculopathy / Albipunctate retinal dystrophy

IndicationStatusPhase
DBCOND0056216 (Retinitis Pigmentosa (RP))Completed1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02110225A Dose Ranging Study to Evaluate the Safety and Potential Efficacy of rhNGF in Patients With Retinitis Pigmentosa (RP)Treatment